NASDAQHealth CareBiotechnologySnapshot 2026-07-31
Reading AGIO? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Successful launch and adoption of AQVESME: metric not reported.
View ThesisRevenue growth is accelerating — up about 141% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 51% in its worst 12-month stretch.
View RiskAGIO's potential U.S. launch of mitapivat in sickle cell disease is critical to justify its current valuation. Revenue grew 260% year over year in the latest quarter, and the company beat earnings expectations. It trades at 29× price-to-sales, significantly above the 8.7× peer median, indicating that the market reflects less growth than AGIO's forecasts suggest. A specific risk is the 32% probability of a miss in the next quarter, which could further pressure the thesis. Peer multiples imply a price about 14% above where it trades. This read is provisional; the thesis is on watch.
Trailing returns as of 2026-07-31. AGIO is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 10 analysts currently covering AGIO (as of Jul 2026).
Based on 3 Wall Street analysts offering 12-month price targets for AGIO in the last 4 months.
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Advances: Potential U.S. launch of mitapivat
FDA priority review boosts potential U.S. launch of mitapivat.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $30.02
The last 12 months of price, then the range of analyst 12-month targets from today’s $30.02.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
FDA-related news likely supports AQVESME launch.
Threatens: Potential U.S. launch of mitapivat
Mitapivat's performance impacts potential U.S. launch.
Strategic expansion supports AQVESME launch objectives.
